|
Bibliografía
1. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361: 1533-44.
2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23.
3. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J
Hum Genet 2000;67:737-44.
4. Humbert M, Sitbon O, Simonneau, G. Treatment of pulmonary hypertension. N Engl J Med 2004;351:1425-36.
5. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115: 343-9.
6. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med1996; 335:609-16.
7. Opravil M, Pechere M, Speich R, et al. HIV-associated primary pulmonary hypertension: a case control study. Am J Respir Crit Care Med 1997;155:990-95.
8. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-44.
9. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002;105:1672-8.
10. Christman B, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med1992;327:70-75.
11. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-32.
12. Bowers R, Cool C, Murphy RC, et al. Oxidative Stress in Severe Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine 2004;169:764-769.
13. Irodova NL, Lankin VZ, Konovalova GK, et al. Oxidative stress in patients with primary pulmonary hypertension. Bull Exp Biol Med. 2002;133:580-2.
14. Hervé P, Launay J, Scrobohaci M, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249-54.
15. Yuan JX, Aldinger AM, Juhaszova M, et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98: 1400-06.
16. Miyamoto S, Nagaya N, Satoh T, et al. Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension. Am J Respir Crit Care Med 2000;161: 487-492.
17. Nauser T, Stites SW. Diagnosis and Treatment of Pulmonary Hypertension. Am Fam Physician 2001;63:1789-98.
18. Humbert M, Nunes H, Sitbon O, et al. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001;22:459-75.
19. Rubin LJ, Rich S. Medical management. In: Rubin L, Rich S, eds. Primary pulmonary hypertension. New York: Marcel Dekker, 1997:271-86.
20. Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogues on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002;26:194-201.
21. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann lntern Med 1994;121:409-15.
22. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
23. Robbins IM, Christman BW, Newman JH, et al. A survey of diagnosticpractices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 1998;114:1269-75.
24. Simonneau G, Barst RJ, Galie N, et al. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2002;165: 800-804.
25. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496–502. 20.
26. Barst RJ, McGoon M, McLaughlin VV, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119–25. 21.
27. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002;347:322–9.
28. Galie` N, Seeger W, Naeije R, et al. Comparative Analysis of Clinical Trials and Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. J Am Coll Cardiol 2004;43:81S– 88S
29. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002;347:322–9.
30. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896–903.
31. Barst R, Langleben D, Frost A, et al. Sitaxsentan, a selective ETA antagonist, improves cardiopulmonary hemodynamics in pulmonary arterial hypertension (abstr). Am Respir Crit Care Med 2003;167:A273.
32. Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric Oxide Pathway and Phosphodiesterase Inhibitors in Pulmonary Arterial Hypertension. J Am Coll Cardiol 2004;43:68S–72S.
33. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725–48.
34. Watanabe H, Ohashi K, Takeuchi K, et al. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 2002;71: 398–402.
35. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398–403.
36. Ghofrani HA et al, Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004;44:1488-96.
37. Gammie JS, Keenan RJ, Pham SM, et al. Single versus double-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1998;115:397-402.
|
Procesando
Inicio
(1)
Reportar abuso
Votar
